Home > Healthcare > Pharmaceuticals > Finished Drug Form > Intravenous Immunoglobulin Market

Intravenous Immunoglobulin Market Size

Report ID: GMI6491
Published Date: Aug 2023
Report Format: PDF

Download Free Sample

Intravenous Immunoglobulin (IVIG) Market Size

Intravenous Immunoglobulin (IVIG) Market size is estimated to have reached USD 10.9 billion in 2022 and is projected to exhibit a compound annual growth rate (CAGR) of 7.6% from 2023 to 2032. This growth is primarily attributed to the escalating prevalence of primary immunodeficiency disorders (PIDs) and secondary immunodeficiencies arising from various medical conditions. Global immunoglobulin industry is estimated to register over 7.4% CAGR between 2023 and 2032 driven by increasing prevalence of immunodeficiency diseases.

To get key market trends

Download Free Sample

Conditions such as common variable immunodeficiency (CVID) and X-linked agammaglobulinemia necessitate regular IVIG infusions to enhance the immune system's functionality. Additionally, IVIG finds utility in the treatment of diverse autoimmune and inflammatory diseases, encompassing immune thrombocytopenic purpura (ITP), Kawasaki disease, and systemic lupus erythematosus (SLE). The rising incidence of these maladies significantly contributes to the heightened requirement for immunoglobulin treatment.

Furthermore, advancements in plasma collection, fractionation, and purification technologies have markedly enhanced the manufacturing and safety standards of IVIG products. These progressive developments have not only broadened the accessibility of plasma derived therapies but have also played a pivotal role in propelling market expansion. Additionally, the growing awareness surrounding immunodeficiency disorders, autoimmune diseases, and the availability of IVIG therapy has resulted in earlier diagnoses and the prompt initiation of treatments. This emerging trend notably bolsters the demand for IVIG services.

Intravenous Immunoglobulin Market Report Attributes
Report Attribute	Details
Base Year:	2022
Intravenous Immunoglobulin Market Size in 2022:	USD 10.9 Billion
Forecast Period:	2023 to 2032
Forecast Period 2023 to 2032 CAGR:	7.6%
2032 Value Projection:	USD 22.6 Billion
Historical Data for:	2018 to 2022
No. of Pages:	127
Tables, Charts & Figures:	226
Segments covered:	Product, Application, Distribution Channel, and Region
Growth Drivers:	Growing prevalence of immunodeficiency disorders Increasing geriatric population Growing advances in plasma collection, fractionation, and purification technologies Increasing healthcare expenditure for immunoglobulins
Pitfalls & Challenges:	High cost of IVIG therapy Potential adverse effects and allergic reactions Scarcity of plasma donors

Learn more about the key segments shaping this market

Download Free Sample

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Intravenous immunoglobulin (IVIG) industry size was USD 10.9 billion in 2022 and is projected to exhibit 7.6% CAGR from 2023 to 2032 attributed to the high prevalence of primary immunodeficiency disorders and secondary immunodeficiencies worldwide.

The IgG segment is poised to record significant growth through 2032 driven by its remarkable versatility, which encompasses a diverse array of functions within the immune system.

North America held 52.3% share of the IVIG market in 2022 and is anticipated to grow at 7.7% CAGR from 2023 to 2032 owing to the high prevalence of immune-mediated diseases, autoimmune disorders, and primary immunodeficiency diseases.

Some of the major companies in the intravenous immunoglobulin industry are Takeda Pharmaceutical Company Limited., Grifols SA, ADMA Biologics, Octapharma AG, Baxter International Inc., LFB Biotechnologies, China Biologics Products Inc., Kedrion Biopharma, and Intas Pharmaceuticals.